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Abstract 
 
Gomisin A (GA) is an active ingredient of the fruits of Schisandra chinensis which has been 
widely used as a tonic in traditional Korean medicine. GA induces not only endothelium-
dependent but also endothelium-independent relaxation in isolated rat thoracic aorta. This 
study was aimed to investigate the molecular mechanism by which GA induces endothelium-
independent vasorelaxation. Rat aortic rings were denuded of endothelium, mounted in organ 
baths, and subjected to contraction or relaxation. We measured the amount of GTP RhoA as 
well as the phosphorylation level of 20 kDa myosin light chains (MLC20), myosin 
phosphatase targeting subunit 1 (MYPT1) and protein kinase C (PKC)-potentiated inhibitory 
protein for heterotrimeric myosin light chain phosphatase (MLCP) of 17kDa (CPI17). 
Pretreatment with GA dose-dependently inhibited the concentration-response curves in 
response to sodium fluoride (NaF) or thromboxane A2 agonist U46619, but not to phorbol 12, 
13-dibutyrate (PDBu). GA decreased the activation of RhoA as well as the phosphorylation 
level of MLC20, MYPT1Thr855 and CPI17 induced by 8.0 mM NaF or 30 nM U46619. 
However, K+ channel blockers such as glibenclamide (GB), apamin (Apa), or charybdotoxin 
(CTX) did not affect the vascular relaxation induced by GA. Furthermore, GA did not affect 
the level of phosphorylation of CPI17 induced by PDBu. GA reduces vascular contraction 
through inhibition of RhoA/Rho-kinase pathway in endothelium-denuded rat aorta.  




GA, Gomisin A; 
MLC20, 20 kDa myosin light chains;  
MLCP, myosin light chain phosphatase;  
MYPT1, myosin phosphatase targeting subunit 1;  
CPI17, PKC-potentiated inhibitory protein for heterotrimeric MLCP of 17kDa;  
NaF, sodium fluoride; 
PDBu, phorbol 12, 13-dibutyrate; 
PKC, protein kinase C;  
GB, glibenclamide;  
Apa, apamin;  
CTX, charybdotoxin;  
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Gomisin A (GA) is a small molecular weight lignan contained in Fructus Schisandrae, the 
dried seed of Schisandra chinensis which is widely used as a health food product and a tonic 
in traditional Korean medicine (Park et al. 2007). Schisandra chinensis have some beneficial 
effects including hepatoprotective, antioxidative, anti-inflammatory, anticancer, and anti-HIV 
actions (Chen et al. 1997; Chiu et al. 2002; Choi et al. 2006; Wu et al. 2003; Yasukawa et al. 
1992). The fruit of Schisandra chinensis is known to be enriched with lignans (Nakajima et al. 
1983), of which schisandrin (2-9%), γ-schisandrin (1-5%), deoxyschisandrin (0.2-1.1%), and 
GA (0.7-3%) are major ingredients, depending on the plant origin and harvest season (% dry 
weight) (He et al. 1997; Park et al. 2007).  
GA or an aqueous extract of Schisandra chinensis induced not only endothelium-
dependent but also endothelium-independent vascular relaxation in isolated thoracic aorta 
through activation of nitric oxide (NO) pathway in endothelium or direct dephosphorylation 
of MLC in vascular smooth muscle (Park et al. 2007; Rhyu et al. 2006). GA releases nitric 
oxide from endothelium through Ca2+-dependent activation and translocation of eNOS (Park 
et al. 2009a). Moreover, the relaxation by GA in endothelium-denuded aortic rings were 
inhibited by calyculin, an inhibitor of MLC phosphatase, implicating involvement of 
RhoA/Rho-kinase signaling pathway which inhibits MLC phosphatase. The small GTPase 
RhoA plays an important role as a molecular switch in the enhancement of Ca2+ sensitivity of 
smooth muscle contraction (Hirata et al. 1992). The activation of RhoA leads to the 
subsequent activation of an effector, Rho-kinase (Leung et al. 1995). Activation of Rho-
kinase decreases the activity of myosin light chain phosphatase (MLCP) through 
phosphorylation of MYPT1 at Thr855 and CPI17 at Thr38, resulting in enhancement of 
vascular contractility (Somlyo et al. 2003). The RhoA/Rho-kinase plays an important role in 
development of cardiovascular diseases such as heart failure, coronary artery disease, 
pulmonary hypertension, arteriosclerosis, restenosis, and stroke which show excessive 
activation of the RhoA/Rho-kinase signaling pathway (Budzyn et al. 2006; Budzyn et al. 
2007; Hirooka et al. 2004; Shimokawa et al. 2005). Recently the RhoA/Rho kinase pathway 
has received attention as genetic disruption of the pathway blocks elevation of vascular tone 
under hypertensive condition without affecting regulation of the blood pressure (Wirth et al. 
2008). 
Here we investigated the mechanism by which GA inhibits vascular smooth muscle 
contraction. Therefore, the purpose of present study was to investigate the inhibitory effects 
of GA on RhoA activation and subsequent phosphorylation of MYPT1 or CPI17 and on 
vascular smooth muscle contraction induced by U46619 or sodium fluoride (NaF). We also 






Schisandra chinensis fruits were collected from Mungyeong, Korea in September 2005. A 
voucher specimen (accession number Schisandra chinensis -PDRL-1) has been deposited in the 
Herbarium of Pusan National University (Park et al. 2009a). Schisandra chinensis was 
identified by our group (Professor Young Whan Choi). 
 
Isolation of GA 
 
The dried fruits of Schisandra chinensis (2.0 kg) were ground to a fine powder and were 
extracted three times with n-hexane in the sonicator. The suspension was filtered, evaporated 
under reduced pressure at low temperature and lyophilized. The brown, oily residue of hexane 
extract (308 g) was obtained. The remnant was extracted again with chloroform and methanol 
sequentially to yield chloroform (14 g) and methanol extract fractions (1368 g). The hexane 
extract (15.2 g) was evaporated in vacuo and chromatographed on a silica gel (40 m, J.T. Baker, 
NJ, USA) column (70 cm×8.0 cm) with a step gradient 0%, 5%, 10%, 20%, 30% ethyl acetate 
in hexane (each 1 L). The fraction 21 (800 mL, 600.5 mg) were separated on a silica gel column 
(100 cm×3.0 cm) with 5% acetone in CH2Cl2 to give a GA (200 mL, 308 mg). Pure GA was 
identified by HPLC on a Phenomenex Luna C18 column (Phenomenex, 150 mm×4.6 mm I.D.; 
5 m particle size).  
The chemical structure of GA was verified by liquid chromatography–mass 
spectrometry (LC–MS, Bruker BioApex FT mass spectrometer) and NMR analysis (Bruker 
DRX 400 spectrometer). Optical rotations were recorded on a JASCO DIP-370 digital 
polarimeter. Infrared spectra were recorded on an AATI Mattson Genesis Series FTIR while 
NMR spectra (1H, 13C) were recorded in CDCl3 on a Bruker DRX 400 spectrometer operating 
at 400MHz for 1H and 100MHz for 13C, running gradients and using residual solvent peaks as 
internal references (Ikeya et al. 1979). High resolution mass spectra were recorded on a Bruker 




The drugs and chemicals were obtained from the following sources: Sodium fluoride (NaF), 
11,9 epoxymethano-prostaglandin F2α (U46619), phorbol 12,13-dibutyrate (PDBu), 
charybdotoxin (CTX), apamin (Apa), glibenclamide (GB), phenylephrine and KCl from 
sigma chemicals (St. Louis, MO, USA). Stock solution of gomisin A, U46619, PDBu and GB 
were prepared in dimethylsulfoxide (DMSO). Stock solution of Apa was prepared in 0.05 M 
acetic acid. All other reagents were analytical grade. 
 
Organ Bath Study  
 
The investigation was conducted in accordance with Guide for the Care and Use of 
Laboratory Animals (Institutional Review Board, Kyungpook National University School of 
Medicine). Male Sprague-Dawley rats, weighing 320-350 g, were used. With animals under 
anesthesia (sodium pentobarbital 50 mg kg-1 i.p.), the thoracic aorta was immediately excised 
and immersed in an ice-cold, modified Krebs solution composed of (in mM) NaCl, 115.0; 
KCl, 4.7; CaCl2, 2.5; MgCl2, 1.2; NaHCO3, 25.0; KH2PO4, 1.2; and dextrose, 10.0. The aorta 
was cleaned of all adherent connective tissue on wet filter paper, soaked in the Krebs-
bicarbonate solution and cut into four ring segments (4 mm in length) as described by Seok’ 
method (Seok et al. 2006). In order to investigate the direct effect of GA in vascular smooth 
muscle, the rings were denuded of endothelium by gently rubbing the internal surface with a 
forcep edge. Two stainless-steel triangles were inserted through each vessel ring. Each aortic 
ring was suspended in a water-jacketed organ bath (22 ml) maintained at 37C and aerated 
with a mixture of 95% O2 and 5% CO2. One triangle was anchored to a stationary support, 
and the other was connected to an isometric force transducer (Grass FT03C, Quincy, Mass., 
USA). The rings were stretched passively by imposing the optimal resting tension, 2.0 g, 
which was maintained throughout the experiment. Each ring was equilibrated in the organ 
bath solution for 90 min before the experiment involving the contractile response to 50 mM 
of KCl addition. Isometric contractions were recorded using a computerized data acquisition 
system (PowerLab/8SP, ADInstruments, Castle Hill, NSW, Australia). To determine the effect 
of GA on NaF, U46619 or PDBu, NaF, U46619 or PDBu were each added into organ baths to 
elicit tension 30 min after pretreatment with GA (0.1 mM, 0.3 mM or 1.0 mM) or vehicle. 
The contractile responses to 8.0 mM NaF, 30 nM U46619 and 0.1 μM PDBu were recorded 
for 40 min, 15 min and 40 min, respectively. To determine the effect of K+ channel blockers, 
K+ channel blockers were pretreated before vascular relaxation were induced by GA. GA or 
vehicle were added cumulatively to elicit relaxation when vascular contraction induced by 
phenylephrine (0.1 μM, 15 min), NaF (8.0 mM, 40 min) or U46619 (30 nM, 15 min) reached 
plateaus in endothelium-denuded rat aortic rings pretreated with glibenclamide (GB, 10 μM), 
apamin (Apa, 500 nM), charybdotoxin (CTX, 10 nM) or vehicle for 20 minutes.  
 
SDS-PAGE for MYPT1 and CPI17   
 
After completion of the functional study, muscle strips were quickly immersed in acetone 
containing 10% trichloroacetic acid (TCA) and 10 mM dithiothreitol (DTT) precooled to -
80C. The aortic rings were washed in acetone containing 5 mM DTT to remove TCA, air-
dried and stored at -80°C until use. Previously stored samples were homogenized in a buffer 
containing 320 mM sucrose, 50 mM Tris, 1 mM EDTA, 1% Triton X-100, 1 mM DTT, and 
protease inhibitors leupeptin (10 μg ml-1), trypsin inhibitor (10 μg ml-1), aprotinin (10 μg ml-1), 
phenylmethylsulfonyl fluoride (PMSF; 100 μg ml-1) and the phosphatase inhibitor sodium 
orthovanadate (Na3VO4; 2 mM). Protein-matched samples (Bradford assay) were 
electrophoresed (SDS-PAGE), transferred to nitrocellulose membranes, and subjected to an 
immunoblot with a p-MYPT1 antibody (1:4,000, Upstate Biotechnology, Lake Placid, NY, 
USA) and a p-CPI17 antibody (1:250, Santa Cruz Biotechnology, Inc) that detect 
phosphorylated MYPT1 and CPI17. Anti-rabbit IgG and anti-goat IgG, conjugated with 
horseradish peroxidase, were used as the secondary antibody (1:4,000, Sigma, St. Louis, MO, 
USA and 1:1,000, Santa Cruz Biotechnology, Inc). The nitrocellulose membranes were 
stripped of the p-MYPT1 and p-CPI17 antibody and reblotted with total MYPT1 antibody 
(1:4,000, BD Biosciences Pharmingen, San Diego, CA, USA) and CPI17 antibody (1:500, 
Upstate Biotechnology, Lake Placid, NY, USA). Anti-mouse IgG and anti-rabbit IgG 
conjugated with horseradish peroxidase were used as the secondary antibody (1:4,000, Sigma, 
St. Louis, MO, USA and 1:1,000, Upstate Biotechnology, Lake Placid, NY, USA). The bands 
containing p-MYPT1, p-CPI17, t-MYPT1 and t-CPI17 were visualized with enhanced 
chemiluminescence (ECL) on films, and then analyzed by a computer-assisted image 
analyzer (Labworks, version 4.5; UVP Inc., Upland, CA). 
 
Urea-PAGE for MLC20 phosphorylation  
 
Muscle strips were quick frozen by immersion in acetone containing 10% TCA and 10 mM 
DTT precooled to -80C. Muscles were washed four times with acetone containing 5 mM 
DTT for 15 minutes each to remove TCA and were soaked 60 minutes with frequent vortex in 
100 μl of urea sample buffer containing 20 mM Tris base·23 mM glycine (pH 8.6), 8.0 M 
urea, 1 M thiourea, 10 mM DTT, 10% glycerol and, 0.04% bromophenol blue. 12.5% 
polyacrylamide gels containing 40% glycerol were pre-electrophoresed for 30 minutes at 300 
V. The running buffer consists of 20 mM Tris base/23 mM glycine (pH 8.6), 0.97 mM 
thioglycolate, and 0.97 mM DTT. The urea-extracted samples (12 μl) were electrophoresed at 
300 V for 6 hours, transferred to nitrocellulose membranes, and subjected to immunoblotting 
with a specific myosin light chain 20 antibody (1:2,000, Sigma, St. Louis, MO, USA). Anti-
mouse IgM (goat), conjugated with horseradish peroxidase, was used as a secondary antibody 
(1:4,000, Assay design, Ann Arbor, MI, USA) (Kim et al. 2004).The bands containing myosin 
light chains were visualized with enhanced chemiluminescence (ECL) on films, and then 
analyzed by a computer-assisted image analyzer (Labworks, version 4.5; UVP Inc., Upland, 
CA). 
 
Assay for RhoA activation   
 
Muscle strips were quick frozen by liquid nitrogen, and kept at -80C. The RhoA assay was 
performed as previously described (Seok et al. 2008), the procedure followed the 
manufacture’s protocol of G-LISATM RhoA Activation Assay Biochem KitTM (Cytoskelecton 
Inc, Denver, CO, USA). Briefly, previously stored samples were homogenized in a lysis 
buffer, and were centrifuged at 13,200 rpm for 15 min at 4C. The resultant supernatants and 
equal volume of ice-cold binding buffer were added into each well for which 37 μg of 
proteins were loaded. The plate was shaken on a cold orbital microplate shaker (300 rpm) for 
30 min at 4C, flicked out of the solution from wells, and incubated with diluted anti-RhoA 
primary antibody followed by secondary antibodies on a microplate shaker (300 rpm) at 
room temperature for 45 min each. The plate was incubated with HRP detection reagent for 
15 min at 37C, after addition of HRP stop buffer, the absorbance was immediately recorded 
at 490 nm. 
  
Statistical analysis  
 
Data are expressed as mean ± SEM and were analyzed by repeated measures analysis of 
variance (ANOVA) for tension measurement and one-way ANOVA followed by Dunnett's 




Effect of GA on vascular contraction induced by NaF, U46619 or PDBu  
 
Thirty minutes after the pretreatment with GA or vehicle, the concentration-response 
relationships to NaF, U46619 or PDBu in endothelium-denuded aortic rings were obtained by 
means of a cumulative addition of the chemicals (Fig. 2). The tension is expressed as a 
percentage to initial contractions in response to 50 mM KCl. Pretreatment with GA inhibited 
the contractile responses to U46619 or NaF, but not to PDBu, an activator of PKC. Emax and 
EC50 for the contractile responses to NaF or U46619 in vehicle and GA preconditioned rat 
aortic strips are shown in Table 1. GA, at 0.3 and 1.0 mM, shifted the EC50 (mM) of the 
concentration–response curve for NaF from 4.9 ± 0.03 to 5.3 ± 0.13 (P < 0.05) and 6.3 ± 0.49 
(P < 0.01) and decreased the Emax (% of the KCl contraction) of the concentration–response 
curve for NaF from 151.8 ± 2.26 to 119.7 ± 3.22 (P < 0.01) and 60.4 ± 5.59 (P < 0.01), 
respectively (Fig. 2a and Table 1). Furthermore, GA (0.3 and 1.0 mM) shifted the EC50 (–log 
M) of the concentration–response curve for U46619 from 8.1 ± 0.07 to 7.7 ± 0.01 (P < 0.05) 
and 7.4 ± 0.05 (P < 0.05) and decreased the Emax (% of the KCl contraction) of the 
concentration–response curve for U46619 from 171.6 ± 0.53 to 120.8 ± 8.11 (P < 0.01) and 
89.9 ± 7.12 (P < 0.01), respectively (Fig. 2b and Table 1). GA alone did not affect basal 
tension (data not shown). 
 
Effect of K+ channel blockers on vascular relaxation induced by GA  
 
Since opening of K+ channels exert vascular relaxation, we investigated whether GA exerts 
vascular relaxation through opening of K+ channels by using K+ channel blockers. Although 
the vehicle did not affect vascular tension induced by phenylephrine, NaF, or U46619, GA 
produced vascular relaxation, which was not affected by pretreatment with glibenclamide, a 
blocker of ATP-sensitive K+ channel (Fig. 3A). In summary, pretreatment with glibenclamide 
(GB, 10 μM), apamin (Apa, 500 nM) or charybdotoxin (CTX, 10 nM) for 20 minutes did not 
affect vascular relaxation induced by GA (Fig. 3). 
 
Inhibitory effect of GA on vascular contraction and MLC20 phosphorylation induced by NaF 
or U46619  
 
In order to investigate whether GA relaxes vascular contraction through regulation of thick 
filament, we determined the level of MLC20 phosphorylation. NaF and U46619 increased 
phosphorylation of MLC20 to 40.7 ± 4.2% or 33.7 ± 1.3%, respectively, in endothelium-
denuded aortic rings. Treatment of rat aortic rings with 0.3 and 1.0 mM GA significantly 
decreased the phosphorylation level of MLC20 (Fig. 4b, d) as well as vascular contraction 
(Fig. 4a, c) induced by NaF or U46619 in endothelium-denuded rat aortic rings. 
 
Inhibitory effect of GA on NaF- or U46619-induced RhoA activation  
 
In order to determine whether GA inhibits RhoA/Rho-kinase pathway, we measured the level 
of GTP RhoA. NaF or U46619 increased the level of GTP RhoA (2.28 ± 0.15 fold or 2.42 ± 
0.17 fold) as compared with the basal level in endothelium-denuded aortic rings. As shown in 
Fig. 5, GA (0.3 or 1.0 mM) nearly totally suppressed (p＜0.05) the level of GTP RhoA 
induced by NaF or U46619. However, GA itself did not affect basal level of GTP RhoA (data 
not shown).  
 
Inhibitory effect of GA on NaF- or U46619-induced MYPT1Thr855 phosphorylation 
 
We determined the level of the phosphorylated MYPT1Thr855, a Rho-kinase substrate. NaF- or 
U46619-stimulated MYPT1Thr855 phosphorylation increased significantly (2.87 ± 0.43 and 
3.10 ± 0.64, respectively) compared with the control. As shown in Fig. 6, GA (0.3 or 1.0 mM) 
decreased the phosphorylation level of MYPT1Thr855 induced by NaF (1.59 ± 0.17 and 1.04 ± 
0.12, respectively) or U46619 (1.48 ± 0.20 and 0.87 ± 0.26, respectively). 
 
Inhibitory effect of GA on NaF- or U46619-induced CPI17Thr38 phosphorylation  
 
The phosphorylation level of CPI17Thr38, another downstream effector of Rho-kinase, was 
measured. NaF or U46619 increased the phosphorylation level of CPI17Thr38 as compared 
with the control in endothelium-denuded rat aortic rings. GA (0.3 or 1.0 mM) decreased the 
phosphorylation level of CPI17Thr38 induced by NaF (0.41 ± 0.07 and 0.29 ± 0.08, 
respectively) (Fig. 7a) or U46619 (0.62 ± 0.05 and 0.37 ± 0.08, respectively) (Fig. 7b). 
 
Effect of Ro31-8220 and GA on PDBu-induced contractions and CPI17Thr38 phosphorylation  
 
The contractile response to 0.1 μM PDBu in aortic rings was obtained 30 min after the 
pretreatment with Ro31-8220 (1.0 μM), GA (1.0 mM) or vehicle (Fig.8a). Pretreatment with 
Ro31-8220, but not with GA, inhibited the vascular contractility and phosphorylation of 
CPI17Thr38 in response to PDBu (Fig. 8a and b). 
Discussion  
 
This study demonstrates that Gomisin A (GA) attenuates vascular contraction through 
inhibition the RhoA/Rho-kinase signaling pathway. GA decreases the activation of RhoA and 
subsequent Rho-kinase dependent phosphorylation of MYPT1Thr855 and CPI17Thr38. GA also 
inhibited the phosphorylation of MLC20 and the contraction in denuded rat aortic rings. 
However, GA did not affect K+ channels or PKC pathway during vascular relaxation. 
The small guanosine triphosphatase RhoA (GTPase RhoA) plays an important role 
as a molecular switch in the enhancement of Ca2+ sensitivity of smooth muscle contraction 
(Kawano et al. 2002). Activation of receptors coupled to trimeric G proteins (Gα12,13) leads, 
through the activity of guanine nucleotide exchange factors (GEFs), to the exchange of GTP 
for GDP on RhoA. GTP RhoA translocates to the plasma membrane, where it interacts with 
Rho-kinase to initiate signaling cascades. When Rho GTPase-activating proteins (RhoGAPs) 
catalyze hydrolysis of GTP bound to RhoA, GDP RhoA reassociates with RhoGDI (Somlyo 
et al. 2003). NaF activate RhoA through activation of G-proteins (Antonny et al. 1993). 
Furthemore, NaF binds and inhibits RhoGAPs, thereby resulting in Rho activation (Vincent et 
al. 1999). U46619 activates GEF upon binding to the thromboxane A2 receptor which is 
coupled to G12/13 (Wilson et al. 2005). The present study showed that NaF and U46619 
activated RhoA approximately 2.3 fold and 2.4 fold over the resting level, respectively (Fig. 
5). These data are consistent with previous reports in which NaF or U46619 activated RhoA 
(Seok et al. 2008; Yang et al. 2009). Furthermore, GA reduced the activation of the RhoA 
induced by NaF or U46619 (Fig. 5). GA may suppress GTP RhoA activation, through 
interaction with GEFs, RhoGAPs or RhoGDI. 
The activity of myosin phosphatase decreases when PKC-potentiated inhibitory 
protein for heterotrimeric MLCP of 17 kDa (CPI17) or myosin phosphatase target subunit 1 
(MYPT1) is phosphorylated (Feng et al. 1999). MLCP is a heterotrimer consisting of a 
catalytic subunit PPIcδ, a 130 kDa regulatory subunit MYPT1 and a 20 kDa subunit of 
unknown function (Hartshorne et al. 1998). We examined the level of phosphorylated 
MYPT1Thr855, which is an inhibitory site and is phosphorylated by the Rho-kinase. Activation 
of Rho-kinase by U46619 or phenylephrine, an α1-adrenergic agonist, phosphorylates 
MYPT1 at Thr855, but not MYPT1 at Thr697 (Tsai et al. 2006; Wilson et al. 2005). The 
phosphorylation of MYPT1Thr697 is independent of the stimulation of G-proteins, Rho-kinase, 
or PKC (Kitazawa et al. 2003; Niiro et al. 2003). We observed that GA inhibited MYPT1Thr855 
phosphorylation induced by U46619 or NaF (Fig. 6). These observations suggest that GA 
inhibits the phosphorylation of MYPT1Thr855 induced by Rho-kinase.  
CPI17 is another downstream effector of Rho-kinase, which was first isolated from 
porcine aorta and identified as a substrate of PKC at Thr38 (Eto et al. 1995). U46619-induced 
CPI17Thr38 phosphorylation was abolished by a Rho-kinase inhibitor Y27632, suggesting that 
Rho-kinase is involved in U46619-induced CPI17 phosphorylation and contractions (Pang et 
al. 2005). These reports showed that U46619 caused CPI17 phosphorylation through 
activation of the RhoA/Rho-kinase pathway, whereas PDBu phosphorylates CPI17 through 
direct activation of protein kinase C pathway. In a separate study of our laboratory, activation 
of Rho-kinase by NaF, or U46619 phosphorylates CPI17Thr38 (Seok et al. 2008; Yang et al. 
2009). Our data also showed that NaF or U46619 significantly increased CPI17Thr38 
phosphorylation, which was inhibited by GA (Fig. 7). However, PDBu-induced CPI17Thr38 
phosphorylation was not inhibited by GA (Fig. 8B).  
It is well known that K+ channels play an important role in the regulation of muscle 
contractility and vascular tone. Because K+ channels are the dominant ion conductive 
pathway in vascular smooth muscle, inhibition of K+ channels lead to membrane 
depolarization and vascular contraction (Jackson 2000; Nelson et al. 1995; Standen et al. 
1998). However, in our experiment (Fig. 3), the relaxant action of GA in the rat aorta did not 
seem to be due to the opening of K+ channels, since the vasorelaxant effects of GA were 
unaffected by pretreatment with glibenclamide (a blocker of ATP-sensitive K+ channels), 
apamin (a blocker of small conductance Ca2+-activated K+ channels) and charybdotoxin (a 
blocker of large-conductance Ca2+-activated K+ channels). These data are in accordance with 
previous report that vasorelaxant action of Schisandra chinensis extracts was unaffected by 
tetraethylammonium, a nonselective blocker of K+ channels (Park et al. 2009b). Smooth 
muscle contraction is mainly regulated by the level of phosphorylation of MLC20, which is 
determined by the opposing action of myosin light chain kinase (MLCK) and MLCP. MLCK 
mediates MLC phosphorylation causing contraction in a Ca2+/calmodulin-dependent manner 
(Kamm et al. 1985). Conversely, MLCP mediates dephosphorylation of phosphorylated MLC 
causing relaxation (Bialojan et al. 1987; Somlyo et al. 1994). Furthermore, activation of Rho-
kinase by NaF or U46619 inhibits the activity of MLCP through phosphorylation of 
regulatory MYPT1Thr855, leading to an increased MLC20 phosphorylation and contraction 
(Wang et al. 2001; Wilson et al. 2005; Yang et al. 2009). In the present study, GA reduced not 
only vascular contraction but also the phosphorylation of MLC20 induced by NaF or U46619 
in endothelium-denuded rat aortic rings (Fig. 4). GA inhibited concentraction-response curves 
to U46619 and to NaF in endothelium-denuded aortic rings. This result is in accordance with 
the finding that GA decreased vascular contraction and MLC20 phosphorylation induced by 
phenylephrine and that ML 9, an inhibitor of MLCK, failed to modify GA-induced relaxation. 
These data suggest that the vasorelaxation by GA is mediated by dephosphorylation of 
phosphorylated MLC through activation of MLCP (Park et al. 2007). 
A dozen of years ago, the Rho-kinase was identified to be involved in development 
of high blood pressure (Uehata et al. 1997). Rho kinase has been identified as an important 
target for treatment of several cardiovascular diseases (Budzyn et al. 2006; Lohn et al. 2009). 
GA decreased vascular contraction induced by NaF or U46619 through inhibition of the 
RhoA/Rho-kinase pathway. Therefore, GA may be a potential lead for development of 
therapeutic drugs. Although GA induces not only endothelium-dependent but also 
endothelium-independent vascular relaxation in isolated thoracic aorta (Park et al. 2007; 
Rhyu et al. 2006), GA may have a main action through activation of nitric oxide (NO) 
pathway in endothelium. However, in some instances such as endothelial dysfunction, it may 
exert endothelium-independent vascular relaxation through activation of activation of 
RhoA/Rho-kinase signaling pathway which inhibits MLC phosphatase. 
In conclusion, GA directly relaxes NaF- and U46619-, but not PDBu-, induced 
vascular contraction in the absence of endothelium. These results suggest that GA attenuates 
vascular contractions through the inhibition of the RhoA/Rho-kinase pathway. However, K+ 
channels are not involved in the vascular relaxation induced by GA.
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Table 1. Maximum contraction (Emax) and EC50 values for the contractile responses to NaF or 





Emax (% KCl) EC50 (mM) Emax (% KCl) EC50 (-log M)
Vehicle 151.8 ± 2.26 4.9 ± 0.03 171.6 ± 0.53 8.1 ± 0.07 
0.1 153.0 ± 2.67 5.0 ± 0.09 171.6 ± 7.73 8.0 ± 0.01 
0.3 119.7 ± 3.22** 5.3 ± 0.13* 120.8 ± 8.11** 7.7 ± 0.01* 
1.0  60.4 ± 5.59** 6.3 ± 0.49** 89.9 ± 7.12** 7.7 ± 0.01* 
 
Data are expressed as means of four experiments, with vertical bars showing SEM. * P < 0.05, 
** P < 0.01 vs. NaF or U46619 alone.  
 
Fig. 1. Chemical structure of gomisin A. 
 
Fig. 2. Effect of gomisin A (GA) on NaF (A)-, U46619 (B)- or PDBu (C)-induced 
contractions. NaF, U46619 or PDBu were each added cumulatively to elicit tension 
30 min after pretreatment with GA or vehicle (DMSO) in denuded rat aortic rings. 
Developed tension is expressed as a percentage of the maximal contraction to 50 mM 
KCl. Data are expressed as means of four experiments with vertical bars showing 
SEM. ** P < 0.01 vs. vehicle. 
 
Fig. 3. Effect of K+ channel blockers pretreatment on vascular relaxation induced by GA. GA 
(0.1, 0.3 or 1.0 mM) or vehicle were added cumulatively to elicit relaxation when 
vascular contraction induced by phenylephrine (0.1 μM), NaF (8.0 mM) or U46619 
(30 nM) reached plateaus in endothelium-denuded rat aortic rings pretreated with 
vehicle, glibenclamide (GB), a blocker of ATP-sensitive K+ channel (10 μM), apamin 
(Apa), a blocker of small conductance Ca2+-activated K+ channel (500 nM), 
charybdotoxin (CTX), a blocker of large-conductance Ca2+-activated K+ channel (10 
nM), for 20 minutes. (A) Representative traces show relaxing responses to GA. 
Developed tension is expressed as a percentage of the maximal contraction to 
phenylephrine (B), NaF (C) or U46619 (D). Data are expressed as the means of four 
experiments with vertical bars showing SEM.  
 
 
Fig. 4. Inhibitory effect of GA on NaF- or U46619-induced MLC20 phosphorylation in rat 
aorta. NaF (8.0 mM) (A) or U46619 (30 nM) (C) were each added to elicit tension 30 
min after pretreatment with GA (0.3 or 1.0 mM) or vehicle to denuded aortic rings. 
Developed tension is expressed as a percentage of the maximum contractions to 50 
mM KCl. (6 aortic rings). When the tension reached plateaus, the phosphorylation 
level of MLC20 in response to NaF (B) or U46619 (D) was measured and was 
expressed as a percentage of the total MLC20 (4 aortic rings). Data are expressed as 
means with vertical bars showing SEM. ** P < 0.01 vs. vehicle (A and C). ## P < 0.01 
vs. control. ** P < 0.01 vs. NaF or U46619 alone (B and D).  
  
Fig. 5. Inhibitory effect of GA on NaF (A)- or U46619 (B)-induced RhoA activation in rat 
aorta. NaF (6.0 mM) or U46619 (30 nM) were each added to elicit tension 30 min 
after pretreatment with GA (0.3 or 1.0 mM) or vehicle to denuded aortic rings. The 
amount of GTP-RhoA was assayed by a RhoA G-LISATM Activation Assay kit. 
Absorbance of the control (OD490 of around 0.4) was expressed as 1 arbitrary unit. 
Data are expressed as means of four experiments, with vertical bars showing SEM. ## 
P < 0.01 vs. control. * P < 0.05, ** P < 0.01 vs. NaF or U46619 alone.  
 
Fig. 6. Inhibitory effect of GA on phosphorylation level of MYPT1Thr855 induced by NaF (A) 
or U46619 (B). NaF (8.0 mM) or U46619 (30 nM) were each added to elicit tension 
30 min after pretreatment with GA (0.3 or 1.0 mM) or vehicle to denuded aortic rings. 
MYPT1 phosphorylation at Thr855 was assessed by western blot. Upper and lower 
bands in representative western blots were probed with anti-pMYPT1 and anti-
tMYPT1 antibodies, respectively. The ratio of density of phosphorylated MYPT1 
(upper) to that of the total MYPT1 (lower) regarding the control was expressed as 1 
arbitrary unit. Data are expressed as the means of four experiments, with vertical bars 
showing SEM. ## P < 0.01 vs. control. * P < 0.05, ** P < 0.01 vs. NaF or U46619 
alone.  
 Fig. 7. Inhibitory effect of GA on phosphorylation of CPI17Thr38 induced by NaF (A) or 
U46619 (B). NaF (8.0 mM) or U46619 (30 nM) were each tension 30 min after 
pretreatment with GA (0.3 or 1.0 mM) or vehicle to denuded aortic rings. CPI17 
phosphorylation at Thr38 was assessed by western blot. Upper and lower bands in 
representative western blots were probed with anti-pCPI17 and anti-tCPI17 antibodies, 
respectively. The ratio of density of phosphorylated CPI17 (upper) to that of the total 
CPI17 (lower) regarding the positive control was expressed as 1 arbitrary unit. Data 
are expressed as means of four experiments with vertical bars showing SEM. ## P < 
0.01 vs. control. ** P < 0.01 vs. NaF or U46619 alone.  
 
Fig. 8. Effect of PKC inhibitor Ro31-8220, or gomisin A on PDBu-induced contraction and 
CPI17 phosphorylation in rat aorta. PDBu (0.1 μM) was added to elicit tension 30 
min after pretreatment with Ro31-8220 (1.0 μM), gomisin A (1.0 mM), or vehicle to 
denuded aortic rings. (A) Developed tension is expressed as a percentage of the 
maximum contractions to 50 mM KCl (4 aortic rings). (B) CPI17 phosphorylation at 
Thr38 was assessed by means of western blot after PDBu treatment. Upper, middle 
and lower bands in representative western blots were probed with anti-pCPI17, anti-
tCPI17 and anti-β-actin antibodies, respectively. The ratio of density of 
phosphorylated CPI17 (upper) to that of total CPI17 (middle) for treatment with 
PDBu was expressed as 1 arbitrary unit. Data are expressed as means of four 
experiments with vertical bars showing SEM. ** P < 0.01 vs. vehicle (A). ## P < 0.01 
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